AR031924A1 - Anticuerpos anti-cd28 silenciados y el uso de estos - Google Patents

Anticuerpos anti-cd28 silenciados y el uso de estos

Info

Publication number: AR031924A1
Authority: AR; Argentina
Prior art keywords: antibodies; silenced; methods; tissues; defective
Prior art date: 2000-12-14

Application number

ARP010105828A

Other languages

English (en)

Spanish (es)

Original Assignee

Fujisawa Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-14

Filing date

2001-12-14

Publication date

2003-10-08

2001-12-14 Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co

2003-10-08 Publication of AR031924A1 publication Critical patent/AR031924A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Transplantation (AREA)
Surgery (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ARP010105828A 2000-12-14 2001-12-14 Anticuerpos anti-cd28 silenciados y el uso de estos AR031924A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US25515500P	2000-12-14	2000-12-14

Publications (1)

Publication Number	Publication Date
AR031924A1 true AR031924A1 (es)	2003-10-08

Family

ID=22967074

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP010105828A AR031924A1 (es)	2000-12-14	2001-12-14	Anticuerpos anti-cd28 silenciados y el uso de estos

Country Status (18)

Country	Link
EP (1)	EP1341553A4 (hu)
JP (1)	JP2004515243A (hu)
KR (1)	KR20040020866A (hu)
CN (1)	CN1272345C (hu)
AR (1)	AR031924A1 (hu)
AU (2)	AU2608602A (hu)
BR (1)	BR0116686A (hu)
CA (1)	CA2432736A1 (hu)
CZ (1)	CZ20031909A3 (hu)
HU (1)	HUP0400697A3 (hu)
IL (1)	IL156262A0 (hu)
MX (1)	MXPA03005327A (hu)
NO (1)	NO20032542L (hu)
NZ (1)	NZ526569A (hu)
PL (1)	PL363239A1 (hu)
RU (1)	RU2261723C2 (hu)
WO (1)	WO2002047721A1 (hu)
ZA (1)	ZA200305384B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080095774A1 (en) *	2001-02-16	2008-04-24	Wyeth	Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en)	2001-02-16	2009-05-12	Genetics Institute Llc	Method for downmodulating immune response in type I diabetes
ES2776657T3 (es)	2005-06-14	2020-07-31	Amgen Inc	Formulaciones de proteínas autotamponantes
FR2951176A1 (fr)	2009-10-09	2011-04-15	Tcl Pharma	Ligands monovalents du recepteur cd28 humain
ES2896149T3 (es) *	2010-02-18	2022-02-24	Ose Immunotherapeutics	Anticuerpos humanizados anti-CD28
CA3040899A1 (en)	2016-10-21	2018-04-26	Amgen Inc.	Pharmaceutical formulations and methods of making the same
US20210251994A1 (en)	2018-06-15	2021-08-19	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
CA3130348A1 (en) *	2019-03-14	2020-09-17	Motti HAKIM	A method for immunosuppression
MA55805A (fr)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V Inc	Métodes de modulation de l'activité immunitaire
EP4076434A1 (en)	2019-12-17	2022-10-26	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (zh)	2020-06-29	2023-05-09	旗舰创业创新五公司	工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
KR20230166150A (ko)	2020-08-19	2023-12-06	젠코어 인코포레이티드	항-cd28 조성물
JP2024512669A (ja)	2021-03-31	2024-03-19	フラグシップパイオニアリングイノベーションズブイ，インコーポレーテッド	タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
CA3224374A1 (en)	2021-06-29	2023-01-05	Flagship Pioneering Innovations V, Inc.	Immune cells engineered to promote thanotransmission and uses thereof
CA3252619A1 (en)	2022-02-23	2023-08-31	Xencor, Inc.	Anti-CD28 and anti-PSMA antibodies
EP4572772A1 (en)	2022-08-17	2025-06-25	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering
WO2024077191A1 (en)	2022-10-05	2024-04-11	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024148336A1 (en) *	2023-01-06	2024-07-11	Igm Biosciences, Inc.	T cell costimulatory multimeric binding molecules and uses thereof
WO2024151687A1 (en)	2023-01-09	2024-07-18	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
US12311033B2 (en)	2023-05-31	2025-05-27	Capstan Therapeutics, Inc.	Lipid nanoparticle formulations and compositions
WO2025076127A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025179294A2 (en)	2024-02-22	2025-08-28	Capstan Therapeutics, Inc.	Immune engineering amplification
WO2025217454A2 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521288A (en) *	1990-03-26	1996-05-28	Bristol-Myers Squibb Company	CD28IG fusion protein

2001
- 2001-12-14 JP JP2002549291A patent/JP2004515243A/ja not_active Withdrawn
- 2001-12-14 EP EP01995504A patent/EP1341553A4/en not_active Withdrawn
- 2001-12-14 CA CA002432736A patent/CA2432736A1/en not_active Abandoned
- 2001-12-14 CN CNB018226361A patent/CN1272345C/zh not_active Expired - Fee Related
- 2001-12-14 HU HU0400697A patent/HUP0400697A3/hu unknown
- 2001-12-14 CZ CZ20031909A patent/CZ20031909A3/cs unknown
- 2001-12-14 KR KR10-2003-7007798A patent/KR20040020866A/ko not_active Ceased
- 2001-12-14 WO PCT/US2001/047955 patent/WO2002047721A1/en not_active Ceased
- 2001-12-14 NZ NZ526569A patent/NZ526569A/en unknown
- 2001-12-14 IL IL15626201A patent/IL156262A0/xx unknown
- 2001-12-14 RU RU2003121231/15A patent/RU2261723C2/ru not_active IP Right Cessation
- 2001-12-14 AU AU2608602A patent/AU2608602A/xx active Pending
- 2001-12-14 PL PL01363239A patent/PL363239A1/xx not_active Application Discontinuation
- 2001-12-14 BR BR0116686-7A patent/BR0116686A/pt not_active IP Right Cessation
- 2001-12-14 AU AU2002226086A patent/AU2002226086C1/en not_active Ceased
- 2001-12-14 AR ARP010105828A patent/AR031924A1/es unknown
- 2001-12-14 MX MXPA03005327A patent/MXPA03005327A/es unknown
2003
- 2003-06-05 NO NO20032542A patent/NO20032542L/no not_active Application Discontinuation
- 2003-07-11 ZA ZA200305384A patent/ZA200305384B/en unknown

Also Published As

Publication number	Publication date
MXPA03005327A (es)	2004-12-03
JP2004515243A (ja)	2004-05-27
RU2261723C2 (ru)	2005-10-10
NZ526569A (en)	2005-07-29
CA2432736A1 (en)	2002-06-20
RU2003121231A (ru)	2005-02-10
NO20032542D0 (no)	2003-06-05
CN1489473A (zh)	2004-04-14
HUP0400697A3 (en)	2007-05-02
WO2002047721A1 (en)	2002-06-20
NO20032542L (no)	2003-08-07
EP1341553A1 (en)	2003-09-10
KR20040020866A (ko)	2004-03-09
HUP0400697A2 (hu)	2004-06-28
BR0116686A (pt)	2003-12-30
AU2002226086B2 (en)	2005-08-25
EP1341553A4 (en)	2004-07-28
IL156262A0 (en)	2004-01-04
CN1272345C (zh)	2006-08-30
AU2608602A (en)	2002-06-24
PL363239A1 (en)	2004-11-15
CZ20031909A3 (cs)	2003-11-12
AU2002226086C1 (en)	2006-03-09
ZA200305384B (en)	2004-10-11

Similar Documents

Publication	Publication Date	Title
AR031924A1 (es)	2003-10-08	Anticuerpos anti-cd28 silenciados y el uso de estos
MX2009003588A (es)	2009-05-28	Composiciones de colageno placentario (telopeptido), natural.
ES2183937T3 (es)	2003-04-01	Inhibidores de la adhesion celular.
ES2157994T3 (es)	2001-09-01	Inhibidores tetra y pentapeptidos sustituidos de la proteina farnesiltransferasa.
ECSP088298A (es)	2008-05-30	Modulacion de la expresion del receptor glucocorticoide
AR023463A1 (es)	2002-09-04	Uso de compuestos de azetidinona
MXPA03001389A (es)	2004-05-04	Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu.
UY24256A1 (es)	1996-06-18	Anticuerpos monoclonales de mono especificos para anticuerpos humanos b 7.1 y/o b7.2, formas primatizadas de los mis- mos, composiciones farmaceuticas que los contienen y uso de los mismos como inmunosupresores
BR0114630A (pt)	2003-07-01	Secretagogos de hormÈnio do crescimento
ECSP045520A (es)	2005-03-10	Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
GT200300031A (es)	2006-05-26	Indazoles substitutos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
ATE529125T1 (de)	2011-11-15	Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
CY1109413T1 (el)	2014-08-13	Μεθοδοι θεραπειας πολλαπλου μυελωματος και διεγειρομενης απο μυελωμα επαναρροφησης οστου χρησιμοποιωντας ανταγωνιστες συνδεσης ιντεγκρινης/υποδοχεα
BR0214029A (pt)	2005-04-19	Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
ECSP088350A (es)	2008-05-30	Pirazolopirimidinas como inhibidores de protein quinasas
ECSP045146A (es)	2004-07-23	Moléculas pequeñas para el tratamiento del crecimiento celular anormal
DE69721021D1 (de)	2003-05-22	Blasenmukosa mit zellen für die rekonstruktion von geweben
ATE526991T1 (de)	2011-10-15	Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
PA8650801A1 (es)	2006-09-22	Composiciones y formulaciones de ecteinascidina, como la ecteinascidina 743
AR052447A1 (es)	2007-03-21	Etansulfonato de 1-(2-metipropil)-1h-imidazo[4,5-c] [1,5] naftiridin-4- amina y metansulfonato de 1-(2- metipropil)-1h-imidazo[4,5 -c] [1,5] naftiridin-4-amina
CO2024005352A2 (es)	2024-05-30	Composiciones de oligonucleótidos y métodos de estas
GT200300046A (es)	2003-10-10	Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
BR0307629A (pt)	2005-01-11	Métodos e composições para tratar condições hiperproliferativas
BRPI0607883A2 (pt)	2009-12-22	método para obter material celular prontamente disponìvel derivado de sangue periférico e uma composição do referido material celular
BR0314369A (pt)	2005-08-09	Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado

Legal Events

Date	Code	Title	Description
2007-06-05	FB	Suspension of granting procedure